Back to News
Market Impact: 0.2
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Source: zacks.com
Healthcare & Biotech
Puma Biotechnology has initiated the Phase II ALISCA-Lung2 trial of alisertib combined with paclitaxel for patients with advanced small-cell lung cancer. The study advances the company’s oncology pipeline, but no efficacy, safety, enrollment, or commercial data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PBYI0.55
More News
- Japan has record 100,000 people aged over 100: How societies are ageing
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters
- Activist Jana Pushes Cooper Cos. to Replace CEO, Board Chair
- ‘No one knows what is in these deals’: Trump set to announce new Medicaid drug pricing model amid affordability concerns
- Theravance Biopharma shareholders approve merger with Zymeworks
- Exclusive-US weighs allowing most pharma licensing deals with China, sources say